Karolinska Dev spins off stake in XSpray Microparticles
Karolinska Development (STO: KDEV) on Tuesday said it has sold off its entire stake in XSpray Microparticles AB without disclosing any financial details.
The Swedish company said it spun off its stake to a consortium led by the Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Recipharm Venture Fund.
Jim Van heusden, chief executive of Karolinska Development, said: “I am very pleased to announce we have concluded the divestment of XSpray Microparticles to an investor consortium led by Östersjöstiftelsen and Recipharm Venture Fund, that also includes XSpray Microparticles’ Board, management and other investors. An important part of this deal is that the consortium will provide the necessary funding to bring XSpray Microparticles to the next value inflection point. Karolinska Development retains an economic interest in the company through an earn-out agreement with potential significant future value”.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze